CEOP in the treatment of systemic non-Hodgkin's lymphoma in AIDS (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

CEOP in the treatment of systemic non-Hodgkin's lymphoma in AIDS (Meeting abstract).

Clinical Oncology Society of Australia Inc. Annual Scientific Meeting: From Laboratory to Clinic--an Integrated Approach to Cancer Research and Therapy. December 4-6, 1991, Sydney, Australia, p. 121, 1991.. Unique Identifier : AIDSLINE ICDB/93686695
Milliken S; Goldstein D; Cooper D; Friedlander M; Penny R; Kelleher A; St. Vincent's Hospital, Sydney, New South Wales 2010, Australia

Abstract: The development of NHL in AIDS conveys a poor prognosis with less than 10% of patients (pts) surviving beyond 2 yr. However, these aggressive tumors often require systemic chemotherapy to bring about effective palliation. In the last year, we have investigated the combination of cyclophosphamide 750 mg/m2, epirubicin 50 mg/m2, vincristine (Oncovin) 2 mg and prednisone 100 mg/day x 5 (CEOP), given at 50-100% dose schedule every 3-4 wk. To date, 17 pts have been treated (16 male, 1 female), age range 27-79 yr (median 35 yr), 7 with immunoblastic, 5 with diffuse large cell, 2 with Burkitt's and 3 undifferentiated lymphomas. Of 15 pts evaluable for response (2 pts too early to assess), 6 pts (40%) achieved a complete remission with 5 (33%) achieving a partial remission for an overall response rate of 73%. Four of 11 evaluable pts remain alive beyond 6 mo (36%). Interestingly, survival and response have correlated with presenting CD4 count or dose intensity. Generally, therapy has been well tolerated with few pts developing greater than grade II WHO toxicity. Preliminary data indicate this to be an effective and tolerable regimen that compares favorably with previously described approaches.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Adult Aged Cyclophosphamide/*THERAPEUTIC USE CD4-Positive T-Lymphocytes Epirubicin/*THERAPEUTIC USE Female Human Leukocyte Count Lymphoma, Non-Hodgkin's/COMPLICATIONS/*DRUG THERAPY/IMMUNOLOGY Male Middle Age Prednisone/*THERAPEUTIC USE Vincristine/*THERAPEUTIC USE ABSTRACT
930228
M9320878

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .